Abstract
Advances in medical imaging are needed to support the general goal of personalized patient-centric care. This is particularly true for prostate cancer, which frequently presents as the initial multifocal disease with variable significance and outcome, and, when aggressive, can recur after the initial definitive management. The combined simultaneous acquisition of multi-parametric magnetic resonance imaging and positron emission tomography (PET) can provide combined structural, metabolic, and functional imaging information regarding prostate cancer status in a whole-body single session examination. As described in this review article, combining PET and MRI appears particularly useful for pelvic disease assessments, as PET and MRI provide complementary information, which can be best obtained with hybrid PET/MR scanners. While there is growing interest in the field of prostate cancer imaging regarding the value of PET/MRI, the current literature in this field is sparse and insufficient for a systematic analysis. This article, therefore, highlights available evidence and future perspectives of PET/MRI for the initial diagnosis, staging, and restaging of prostate cancer with choline-based radiotracers as well as ligands to target prostate-specific membrane antigen.
Similar content being viewed by others
References
American Cancer Society (2012) Cancer facts and figures. Atlanta
Robertson NL, Emberton M, Moore CM (2013) MRI-targeted prostate biopsy: a review of technique and results. Nat Rev Urol 10:589–597. doi:10.1038/nrurol.2013.196
Klotz L, Emberton M (2014) Management of low risk prostate cancer: active surveillance and focal therapy. Curr Opin Urol 24:270–279. doi:10.1097/MOU.0000000000000055
Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI (2012) Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes? Am J Surg Pathol 36:1346–1352. doi:10.1097/PAS.0b013e3182556dcd
Klotz L, Emberton M (2014) Management of low risk prostate cancer-active surveillance and focal therapy. Nat Rev Clin Oncol 11:324–334. doi:10.1038/nrclinonc.2014.73
Rischke HC, Eiberger AK, Volegova-Neher N, Henne K, Krauss T, Grosu AL et al (2016) PET/CT and MRI directed extended salvage radiotherapy in recurrent prostate cancer with lymph node metastases. Adv Med Sci 61:212–218. doi:10.1016/j.advms.2016.01.003
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T et al (2014) EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65:124–137. doi:10.1016/j.eururo.2013.09.046
Evangelista L, Briganti A, Fanti S, Joniau S, Reske S, Schiavina R et al (2016) New clinical indications for F/C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature. Eur Urol. doi:10.1016/j.eururo.2016.01.029
Kitajima K, Murphy RC, Nathan MA, Froemming AT, Hagen CE, Takahashi N et al (2014) Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. J Nucl Med 55:223–232. doi:10.2967/jnumed.113.123018
Fanti S, Minozzi S, Castellucci P, Balduzzi S, Herrmann K, Krause BJ et al (2016) PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. Eur J Nucl Med Mol Imaging 43:55–69. doi:10.1007/s00259-015-3202-7
Umbehr MH, Muntener M, Hany T, Sulser T, Bachmann LM (2013) The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol 64:106–117. doi:10.1016/j.eururo.2013.04.019
Turkbey B, Bernardo M, Merino MJ, Wood BJ, Pinto PA, Choyke PL (2012) MRI of localized prostate cancer: coming of age in the PSA era. Diagn Interv Radiol 18:34–45. doi:10.4261/1305-3825.DIR.4478-11.1
Turkbey B, Pinto PA, Mani H, Bernardo M, Pang Y, McKinney YL et al (2010) Prostate cancer: value of multiparametric MR imaging at 3 T for detection—histopathologic correlation. Radiology 255:89–99. doi:10.1148/radiol.09090475
Quon JS, Moosavi B, Khanna M, Flood TA, Lim CS, Schieda N (2015) False positive and false negative diagnoses of prostate cancer at multi-parametric prostate MRI in active surveillance. Insights Imaging 6:449–463. doi:10.1007/s13244-015-0411-3
De Visschere PJ, Briganti A, Futterer JJ, Ghadjar P, Isbarn H, Massard C et al (2016) Role of multiparametric magnetic resonance imaging in early detection of prostate cancer. Insights Imaging 7:205–214. doi:10.1007/s13244-016-0466-9
Futterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A et al (2015) Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol 68:1045–1053. doi:10.1016/j.eururo.2015.01.013
Rais-Bahrami S, Siddiqui MM, Turkbey B, Stamatakis L, Logan J, Hoang AN et al (2013) Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer. J Urol 190:1721–1727. doi:10.1016/j.juro.2013.05.052
Wetter A, Lipponer C, Nensa F, Beiderwellen K, Olbricht T, Rubben H et al (2013) Simultaneous 18F choline positron emission tomography/magnetic resonance imaging of the prostate: initial results. Invest Radiol 48:256–262. doi:10.1097/RLI.0b013e318282c654
Hartenbach M, Hartenbach S, Bechtloff W, Danz B, Kraft K, Klemenz B et al (2014) Combined PET/MRI improves diagnostic accuracy in patients with prostate cancer: a prospective diagnostic trial. Clin Cancer Res 20:3244–3253. doi:10.1158/1078-0432.CCR-13-2653
Meyer C, Ma B, Kunju LP, Davenport M, Piert M (2013) Challenges in accurate registration of 3-D medical imaging and histopathology in primary prostate cancer. Eur J Nucl Med Mol Imaging 40(Suppl 1):72–78. doi:10.1007/s00259-013-2382-2
Y-i Kim, Cheon GJ, Paeng JC, Cho JY, Kwak C, Kang KW et al (2015) Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous 18F-fluorocholine PET/MRI for primary prostate cancer characterization. Eur J Nucl Med Mol Imaging 42:1247–1256. doi:10.1007/s00259-015-3026-5
Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I et al (2016) Simultaneous Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol. doi:10.1016/j.eururo.2015.12.053
Turkbey B, Aras O, Karabulut N, Turgut AT, Akpinar E, Alibek S et al (2012) Diffusion-weighted MRI for detecting and monitoring cancer: a review of current applications in body imaging. Diagn Interv Radiol 18:46–59. doi:10.4261/1305-3825.DIR.4708-11.2
Varoquaux A, Rager O, Lovblad KO, Masterson K, Dulguerov P, Ratib O et al (2013) Functional imaging of head and neck squamous cell carcinoma with diffusion-weighted MRI and FDG PET/CT: quantitative analysis of ADC and SUV. Eur J Nucl Med Mol Imaging 40:842–852. doi:10.1007/s00259-013-2351-9
Baba S, Isoda T, Maruoka Y, Kitamura Y, Sasaki M, Yoshida T et al (2014) Diagnostic and prognostic value of pretreatment SUV in 18F-FDG/PET in breast cancer: comparison with apparent diffusion coefficient from diffusion-weighted MR imaging. J Nucl Med 55:736–742. doi:10.2967/jnumed.113.129395
Wetter A, Lipponer C, Nensa F, Heusch P, Rubben H, Schlosser TW et al (2014) Quantitative evaluation of bone metastases from prostate cancer with simultaneous [18F]choline PET/MRI: combined SUV and ADC analysis. Ann Nucl Med 28:405–410. doi:10.1007/s12149-014-0825-x
Park H, Wood D, Hussain H, Meyer CR, Shah RB, Johnson TD et al (2012) Introducing parametric fusion PET/MRI of primary prostate cancer. J Nucl Med 53:546–551. doi:10.2967/jnumed.111.091421
Gatidis S, Scharpf M, Martirosian P, Bezrukov I, Kustner T, Hennenlotter J et al (2015) Combined unsupervised–supervised classification of multiparametric PET/MRI data: application to prostate cancer. NMR Biomed 28:914–922. doi:10.1002/nbm.3329
Penson DF (2012) Factors influencing patients’ acceptance and adherence to active surveillance. J Natl Cancer Inst Monogr 2012:207–212. doi:10.1093/jncimonographs/lgs024
Pinto PA, Chung PH, Rastinehad AR, Baccala AA Jr, Kruecker J, Benjamin CJ et al (2011) Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol 186:1281–1285. doi:10.1016/j.juro.2011.05.078
Schimmoller L, Quentin M, Arsov C, Hiester A, Buchbender C, Rabenalt R et al (2014) MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy. Eur Radiol 24:2582–2589. doi:10.1007/s00330-014-3276-9
Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N et al (2015) Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 313:390–397. doi:10.1001/jama.2014.17942
Abd-Alazeez M, Ahmed HU, Arya M, Charman SC, Anastasiadis E, Freeman A et al (2014) The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level—can it rule out clinically significant prostate cancer? Urol Oncol 32(45):e17–e22. doi:10.1016/j.urolonc.2013.06.007
Thompson JE, Moses D, Shnier R, Brenner P, Delprado W, Ponsky L et al (2014) Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study. J Urol 192:67–74. doi:10.1016/j.juro.2014.01.014
Jadvar H, Colletti PM (2014) Competitive advantage of PET/MRI. Eur J Radiol 83:84–94. doi:10.1016/j.ejrad.2013.05.028
Takei T, Souvatzoglou M, Beer AJ, Drzezga A, Ziegler S, Rummeny EJ et al (2012) A case of multimodality multiparametric 11C-choline PET/MR for biopsy targeting in prior biopsy-negative primary prostate cancer. Clin Nucl Med 37:918–919. doi:10.1097/RLU.0b013e31825b23a6
Piert M, Montgomery J, Kunju LP, Siddiqui J, Rogers V, Rajendiran T et al (2016) 18F-choline PET/MRI: the additional value of PET for MRI-guided transrectal prostate biopsies. J Nucl Med. doi:10.2967/jnumed.115.170878
Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P et al (2012) Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 48:441–446. doi:10.1016/j.ejca.2011.11.036
El Naqa I, Grigsby P, Apte A, Kidd E, Donnelly E, Khullar D et al (2009) Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern Recognit 42:1162–1171. doi:10.1016/j.patcog.2008.08.011
Naqa IE (2014) The role of quantitative PET in predicting cancer treatment outcomes. Clin Transl Imaging 2:305–320. doi:10.1007/s40336-014-0063-1
Parmar C, Grossmann P, Bussink J, Lambin P, Aerts HJ (2015) Machine learning methods for quantitative radiomic biomarkers. Sci Rep 5:13087. doi:10.1038/srep13087
Khalvati F, Wong A, Haider MA (2015) Automated prostate cancer detection via comprehensive multi-parametric magnetic resonance imaging texture feature models. BMC Med Imaging 15:27. doi:10.1186/s12880-015-0069-9
Cameron A, Khalvati F, Haider M, Wong A (2015) MAPS: a quantitative radiomics approach for prostate cancer detection. IEEE Trans Biomed Eng. doi:10.1109/TBME.2015.2485779
Fehr D, Veeraraghavan H, Wibmer A, Gondo T, Matsumoto K, Vargas HA et al (2015) Automatic classification of prostate cancer Gleason scores from multiparametric magnetic resonance images. Proc Natl Acad Sci USA 112:E6265–E6273. doi:10.1073/pnas.1505935112
Mapelli P, Panebianco V, Picchio M (2015) Prostate cancer recurrence: can PSA guide imaging? Eur J Nucl Med Mol Imaging 42:1781–1783. doi:10.1007/s00259-015-3091-9
Reske SN, Blumstein NM, Glatting G (2008) [(11)C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 35:9–17
Souvatzoglou M, Krause BJ, Purschel A, Thamm R, Schuster T, Buck AK et al (2011) Influence of (11)C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiother Oncol 99:193–200. doi:10.1016/j.radonc.2011.05.005
Souvatzoglou M, Eiber M, Takei T, Furst S, Maurer T, Gaertner F et al (2013) Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer. Eur J Nucl Med Mol Imaging 40:1486–1499. doi:10.1007/s00259-013-2467-y
Hauth E, Hohmuth H, Cozub-Poetica C, Bernand S, Beer M, Jaeger H (2015) Multiparametric MRI of the prostate with three functional techniques in patients with PSA elevation before initial TRUS-guided biopsy. Br J Radiol 88:20150422. doi:10.1259/bjr.20150422
Grant K, Lindenberg ML, Shebel H, Pang Y, Agarwal HK, Bernardo M et al (2013) Functional and molecular imaging of localized and recurrent prostate cancer. Eur J Nucl Med Mol Imaging. doi:10.1007/s00259-013-2419-6
Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M et al (2015) The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42:197–209. doi:10.1007/s00259-014-2949-6
Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M et al (2014) Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging 41:887–897. doi:10.1007/s00259-013-2660-z
Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG et al (2014) Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41:11–20. doi:10.1007/s00259-013-2525-5
Giovacchini G, Picchio M, Garcia-Parra R, Mapelli P, Briganti A, Montorsi F et al (2013) [11C]choline positron emission tomography/computerized tomography for early detection of prostate cancer recurrence in patients with low increasing prostate specific antigen. J Urol 189:105–110. doi:10.1016/j.juro.2012.09.001
Fortuin A, Rooij M, Zamecnik P, Haberkorn U, Barentsz J (2013) Molecular and functional imaging for detection of lymph node metastases in prostate cancer. Int J Mol Sci 14:13842–13875. doi:10.3390/ijms140713842
Hovels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL et al (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63:387–395. doi:10.1016/j.crad.2007.05.022
Thoeny HC, Froehlich JM, Triantafyllou M, Huesler J, Bains LJ, Vermathen P et al (2014) Metastases in normal-sized pelvic lymph nodes: detection with diffusion-weighted MR imaging. Radiology 273:125–135. doi:10.1148/radiol.14132921
Rauscher I, Eiber M, Souvatzoglou M, Schwaiger M, Beer AJ (2014) PET/MR in oncology: non-18F-FDG tracers for routine applications. J Nucl Med 55:25S–31S. doi:10.2967/jnumed.113.129536
Piccardo A, Paparo F, Picazzo R, Naseri M, Ricci P, Marziano A et al (2014) Value of fused 18F-Choline-PET/MRI to evaluate prostate cancer relapse in patients showing biochemical recurrence after EBRT: preliminary results. BioMed Res Int 2014:103718. doi:10.1155/2014/103718
Beer AJ, Eiber M, Souvatzoglou M, Holzapfel K, Ganter C, Weirich G et al (2011) Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in (11)C-Choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer. Mol Imaging Biol 13:352–361. doi:10.1007/s11307-010-0337-6
Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G et al (2015) Diagnostic efficacy of Gallium-PSMA positron emission tomography compared to conventional imaging in lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. doi:10.1016/j.juro.2015.12.025
Freitag MT, Radtke JP, Hadaschik BA, Kopp-Schneider A, Eder M, Kopka K et al (2016) Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging 43:70–83. doi:10.1007/s00259-015-3206-3
Beheshti M, Langsteger W, Fogelman I (2009) Prostate cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med 39:396–407. doi:10.1053/j.semnuclmed.2009.05.003
Shen G, Deng H, Hu S, Jia Z (2014) Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skelet Radiol 43:1503–1513. doi:10.1007/s00256-014-1903-9
Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT (2007) Imaging prostate cancer: a multidisciplinary perspective. Radiology 243:28–53. doi:10.1148/radiol.2431030580
Lecouvet FE, El Mouedden J, Collette L, Coche E, Danse E, Jamar F et al (2012) Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 62:68–75. doi:10.1016/j.eururo.2012.02.020
Picchio M, Spinapolice EG, Fallanca F, Crivellaro C, Giovacchini G, Gianolli L et al (2012) [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging 39:13–26. doi:10.1007/s00259-011-1920-z
Beer AJ, Eiber M, Souvatzoglou M, Schwaiger M, Krause BJ (2011) Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol 12:181–191. doi:10.1016/S1470-2045(10)70103-0
Eschmann SM, Pfannenberg AC, Rieger A, Aschoff P, Muller M, Paulsen F et al (2007) Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer. Nuklearmedizin 46:161–168 (quiz N47-8)
Souvatzoglou M, Eiber M, Martinez-Moeller A, Furst S, Holzapfel K, Maurer T et al (2013) PET/MR in prostate cancer: technical aspects and potential diagnostic value. Eur J Nucl Med Mol Imaging 40(Suppl 1):S79–S88. doi:10.1007/s00259-013-2445-4
Kabasakal L, Demirci E, Ocak M, Akyel R, Nematyazar J, Aygun A et al (2015) Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl Med Commun 36:582–587. doi:10.1097/MNM.0000000000000290
Maurer T, Beer AJ, Wester HJ, Kubler H, Schwaiger M, Eiber M (2014) Positron emission tomography/magnetic resonance imaging with 68Gallium-labeled ligand of prostate-specific membrane antigen: promising novel option in prostate cancer imaging? Int J Urol 21:1286–1288. doi:10.1111/iju.12577
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The research leading to stated results in Figs. 1 and 2 was funded by the US Department of Defense (DOD) Grant PC110389.
Conflict of interest
All six authors (Morand Piert, Issam El Naqa, Mathew S. Davenport, Elena Incerti, Paola Mapelli, and Maria Picchio) have no conflicts of interest.
Ethical approval
The institutional ethics committee of the University of Michigan approved protocols related to presented patient data in Figs. 1 and 2. Written informed consent was obtained. Otherwise, this article does not contain any studies with human or animal subjects performed by any of the authors.
Rights and permissions
About this article
Cite this article
Piert, M., El Naqa, I., Davenport, M.S. et al. PET/MRI and prostate cancer. Clin Transl Imaging 4, 473–485 (2016). https://doi.org/10.1007/s40336-016-0192-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40336-016-0192-9